Informaticians at Spain's National Cancer Research Centre develop a methodology for evaluating likely drug efficacy based on specific patient genotypes.
The firm hopes the effort, recently described in the journal Oncotarget, will spur adoption of its testing services by oncologists, particularly in Europe, where it is determined to become a market leader.
The effort, which relied on Oxford BioDynamics' EpiSwitch platform, resulted in an assay that researchers believe could be developed into a test to guide therapy selection for patients.
Given the high yield of miRNA markers they were able to isolate, the researchers believe the approach could be commercialized for routine cancer testing.
A Johns Hopkins team reported its finding in JAMA Cardiology, backed by SNP array data from 21,870 participants culled from several large cardiovascular studies.
Scientists reported this week for the first time a Danish reference genome based on the de novo assembly of 150 genomes from 50 family trios.
September's Bioinformatics Papers of Note
Bernstein BE, Birney E, et al.An integrated encyclopedia of DNA elements in the human genome.Nature. 2012 Sep 6;489(7414):57-74.
Next-generation sequencing identifies novel microRNAs in peripheral blood of lung cancer patients.
Keller A, Backes C, Leidinger P, et al.Mol Biosyst. 2011 Oct 25. [Epub ahead of print]
First survey of the wheat chromosome 5A composition through a next generation sequencing approach.
Vitulo N, Albiero A, Forcato C, et al.PLoS One. 2011;6(10):e26421.
Bioinformatics Tool-Related Papers of Note, October 2011
Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.
Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.
A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.
In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.